Evidence map›Paper›PMID 35276093›Full record

ArticleThe Lancet. Public health2022

Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study.

Sarah M Bartsch, Kelly J O'Shea, Kevin L Chin, Ulrich Strych, Marie C Ferguson, Maria Elena Bottazzi, Patrick T Wedlock, Sarah N Cox, Sheryl S Siegmund, Peter J Hotez and 1 more

Abstract read
In one paragraph

Article in The Lancet. Public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA.Applied health economics and health policy · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sarah M BartschCenter for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA.
Kelly J O'SheaCenter for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA.
Kevin L ChinCenter for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA.
Ulrich StrychNational School of Tropical Medicine and Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Marie C FergusonCenter for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA.
Maria Elena BottazziNational School of Tropical Medicine and Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Patrick T WedlockCenter for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA.
Sarah N CoxCenter for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA.
Sheryl S SiegmundCenter for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA.
Peter J HotezNational School of Tropical Medicine and Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Bruce Y LeeCenter for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA. Electronic address: bruceleemdmba@gmail.com.

Funding

Project 4: Virtual Public Health Precision Nutrition LaboratoryU54TR004279 · NCATS · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI Bruce Y Lee · 2022 to 2026
$5.4M
Regional Healthcare Ecosystem Analyst (RHEA) Modeling the Environment (MODE): SARS-CoV-2R01GM127512 · NIGMS · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI LEE, BRUCE Y · 2020 to 2023
$2.1M
MOdeling Nursing homes to Affect Response to COVID-19 (MONARC)R01HS028165 · AHRQ · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI LEE, BRUCE Y · 2021 to 2022
$993k
AHRQ HHS R01 HS028165NCATS NIH HHS U54 TR004279NIGMS NIH HHS R01 GM127512
6 · The paper itself

Abstract

backgroundFace mask wearing has been an important part of the response to the COVID-19 pandemic. As vaccination coverage progresses in countries, relaxation of such practices is increasing. Subsequent COVID-19 surges have raised the questions of whether face masks should be encouraged or required and for how long. Here, we aim to assess the value of maintaining face masks use indoors according to different COVID-19 vaccination coverage levels in the USA.

methodsIn this computational simulation-model study, we developed and used a Monte Carlo simulation model representing the US population and SARS-CoV-2 spread. Simulation experiments compared what would happen if face masks were used versus not used until given final vaccination coverages were achieved. Different scenarios varied the target vaccination coverage (70-90%), the date these coverages were achieved (Jan 1, 2022, to July 1, 2022), and the date the population discontinued wearing face masks.

findingsSimulation experiments revealed that maintaining face mask use (at the coverage seen in the USA from March, 2020, to July, 2020) until target vaccination coverages were achieved was cost-effective and in many cases cost saving from both the societal and third-party payer perspectives across nearly all scenarios explored. Face mask use was estimated to be cost-effective and usually cost saving when the cost of face masks per person per day was ≤US$1·25. In all scenarios, it was estimated to be cost-effective to maintain face mask use for about 2-10 weeks beyond the date that target vaccination coverage (70-90%) was achieved, with this added duration being longer when the target coverage was achieved during winter versus summer. Factors that might increase the transmissibility of the virus (eg, emergence of the delta [B.1.617.2] and omicron [B.1.1.529] variants), or decrease vaccine effectiveness (eg, waning immunity or escape variants), or increase social interactions among certain segments of the population, only increased the cost savings or cost-effectiveness provided by maintaining face mask use.

interpretationOur study provides strong support for maintaining face mask use until and a short time after achieving various final vaccination coverage levels, given that maintaining face mask use can be not just cost-effective, but even cost saving. The emergence of the omicron variant and the prospect of future variants that might be more transmissible and reduce vaccine effectiveness only increases the value of face masks.

fundingThe Agency for Healthcare Research and Quality, the National Institute of General Medical Sciences, the National Science Foundation, the National Center for Advancing Translational Sciences, and the City University of New York.

Indexed as

COVID-19Vaccination CoverageCOVID-19 VaccinesHumansMasksPandemicsSARS-CoV-2COVID-19 Vaccines

Identifiers

PMID35276093
PMCPMC8903840

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.